Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasisFARMINGTON HILLS, Mich., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that it will pre
Source: yahoo.com